Related Experiment Videos
Insights from Secular Trend of Major Osteoporotic Fractures in People with and without Diabetes: 15-Year
David T W Lui1, Xincheng Zou2, Chi-Ho Lee2
1Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China; Asia Pacific Consortium on Osteoporosis (APCO), Hong Kong SAR, China.
Objective:
This study aims to evaluate changes in the epidemiology of major osteoporotic fractures (MOF) stratified by diabetes status over 15 years in a population-based cohort.
Methods:
Individuals aged ≥50 years who sustained MOF between 2009 and 2023 identified from territory-wide electronic health database, stratified by diabetes status. Records of HbA1c, hypoglycemic episodes, and osteoporosis screening and treatments were retrieved. Ratios of rates of MOF, osteoporosis screening and treatments between the diabetes and nondiabetes groups were calculated to reflect the disparity between 2 groups. Secular trends were reported in average annual percentage change (AAPC) using joinpoint regression. All rates were age-standardized to the 2021 Hong Kong Census mid-year population.
Results:
86 263 hip fractures and 124 268 nonhip fractures were recorded during the study period. Although annual age-standardized incidence of hip fractures decreased, rate ratios between diabetes and nondiabetes remained static at 4.1 for women (AAPC: -0.16%, 95% CI: -0.65 to +0.35, P = .54) and 2.5 for men (AAPC: +0.07%, 95%CI: -0.58 to 0.71, P = .83), suggesting persistent gap of diabetes-specific excess fracture risk. This gap was similarly observed for nonhip fractures. Over the years, age-standardized mean HbA1c improved from 59 mmol/mol (7.5%) to 53 mmol/mol (7%), along with fewer severe hypoglycemic episodes. Prevalence of individuals with screening dual-energy x-ray absorptiometry performed increased, more so in women with diabetes. Anti-osteoporosis medication prescriptions increased in both diabetes and nondiabetes, but increased to a lesser extent in the diabetes population.
Conclusion:
Diabetes-specific excess fracture risk persisted despite improved glycemic control. Despite increasing efforts of osteoporosis screening in diabetes, this has not translated into more aggressive treatment of bone fragility in diabetes.
Related Concept Videos
01:29Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:31Osteoclasts in Bone Remodeling
01:25Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
01:09Changes in the Appendicular Skeleton with Age
Initially, the limb buds consist of a core of mesenchyme covered by a layer of ectoderm. The ectoderm at the end of the limb bud thickens to form a narrow crest called the apical ectodermal ridge. This ridge stimulates the underlying...
01:27Fractures: Bone Repair
Minor fractures with no bone displacement are treated by immobilizing the fractured bone using a cast or splint. However, in the case of fractures with displaced bones, the broken bones are repositioned before immobilization to ensure successful healing without deformation and loss of function. The realignment of fractured bone ends is performed through a process called reduction. If the procedure...
01:24Type II Diabetes II: Pathophysiology